MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
Company: Pfizer Inc.
Headquarters: New York, USA
Here are the drug patents we want Pfizer to put in the pool and why patients need them
Maraviroc (MVC)
Brand name: Selzentry
Maraviroc is one of a very new class of antiretrovirals that works in a totally new way to fight the HIV virus. This drug is used in the US and Europe by patients who have hit the end of the road with other available treatments. It could transform the prospects of some patients in developing countries who have also run out of treatment options. But Pfizer has indicated it won’t offer reduced prices for patients in developing countries. That’s why it’s very important to get the patents of this drug in the pool.
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
